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The association between invasive cervical carcinoma and human papillomavirus (HPV) has now been established beyond doubt, but
this is not necessarily a direct-and-effect association. To assess the causality of HPV, we analyzed HPV genomes in squamous cell
carcinomas (SCCS) of the uterine cervix by both blot hybridization and PCR. Genital HPV sequences were found in 231 (79%) of 294
SCCs by blot hybridization with more than five copies of entire HPV genomes identified in some cases including HPV 16 (92 cases),
HPV 58 (32 cases), and HPV 52 (24 cases). By PCR-direct sequence analysis in 250 of 294 SCCs, genital HPV sequences were found in
240 samples (96%). The partial L1 sequences of HPV 16 were identified in 123 cases, and those of HPVs 18 and 31 were found in 24
and 20 cases, respectively. In addition, multiple HPV types were identified in 29 (12%) of 250 SCCs, and the HPV copy number, detected
by PCR only, was less than 0.05. Marked discrepancies were therefore evident between the two analytical techniques. In this report, we
discuss the causality of HPV for SCC with regard to the length of the viral genome, the amount of viral DNA, and multiple HPVs in
single SCCs.
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Invasive cervical carcinoma (ICC) consists of three
histological types, squamous cell carcinoma (SCC), ade-
nocarcinoma, and adenosquamous carcinoma, and it is a
prevalent malignancy in women worldwide. It has been
established through extensive epidemiological studies that
human papillomavirus (HPV) is both necessary and causal
for ICC. HPV is ubiquitous worldwide and is markedly
heterogeneous, such that 88 different genotypes have so far
been identified by nucleotide sequence similarity (Terai
and Burk, 2002). Nevertheless, most HPVs have also been
clearly classified into high-risk and low-risk groups for
SCC by statistical analysis (Mun˜oz et al., 2003). The
association of HPV and SCC fulfills the established criteria0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.03.017
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E-mail address: sugase@nagano-med.jrc.or.jp (M. Sugase).for causal postulates, but is not necessarily, however, a
direct-and-effect association (Wright and Schiffman, 2003).
HPVs 16 and 18 are predominantly associated with ICCs
worldwide (Bosch et al., 1995), whereas other HPV types
tend to be associated with ICC at specific geographical
regions. In addition, HPV 18 is also predominantly asso-
ciated with adenocarcinoma worldwide. The reasons for
these specificities are still unknown, and furthermore, it
seems problematic to specify a causal HPV species when
multiple HPVs are evident in single ICCs.
Because extensive studies have been performed by PCR
that target partial viral sequences, there is little current
knowledge of the lengths of the viral genomes that have
been analyzed or of the actual amount of viral DNA in
ICC. Therefore, in the present study, we precisely analyzed
HPV genomes in fresh unfixed SCC tissue specimens by
blot hybridization and PCR. We discuss the causality of
HPV with regard to the amount of viral DNA, the length of
the viral genome, and the presence of multiple HPVs in
individual SCCs.
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Detection and identification of HPV by blot hybridization
We first examined SCC specimens by blot hybridization
with an HPV 58 probe at Tm 40 jC, which is effective in
identifying HPV in either cervical intraepithelial neoplasiaTable 1
Genital and skin groups of human papillomaviruses
Genital
group
HPV
type
[GC%] Genome
similaritya
Skin
group
HPV
type
[GC%] Genome
similarity
A3 (G1)b 61 [46] 100 A4(S1) 2 [48] 100
62 NT NT 27 [49] 90
72 [46] 79 57 [50] 82
81 [45] 73 None(S2) 41 [47] NT
83 [46] 70 A2(S3) 3 [46] 100
84 [46] 70 10 [46] 81
86 [46] 69 28 [46] 84
87 [45] 70 29 [46] 77
89 [46] 71 77 [46] 76
A15(G2) 71 [44] 100 78 [46] 79
90 [40] 71 B1(S4) 5 [42] 100
A8(G3) 7 [40] 100 8 [43] 78
40 [44] 83 9 [41] 63
43 [40] 70 12 [42] 78
79 NT NT 14 [41] 71
91 [40] 67 15 [40] 64
A10(G4) 6 [41] 100 17 [41] 63
11 [41] 83 19 [41] 73
13 [39] 75 20 [41] 73
44 [41] 74 21 [41] 73
74 [41] 73 22 [40] 63
A1(G5) 32 [41] 100 23 [40] 63
42 [40] 78 24 [40] 69
A7(G6) 18 [40] 100 25 [42] 73
39 [40] 70 36 [42] 83
45 [40] 80 37 [41] 64
54 [42] 62 38 [41] 63
59 [39] 71 47 [42] 79
68 NT NT 49 [41] 64
70 [40] 71 75 [41] 64
85 [38] 72 76 [42] 64
A6(G7) 30 [40] 100 80 [40] 64
53 [40] 82 92 [40] 63
56 [38] 75 E1(S5) 1 [40] 100
66 [38] 75 63 [40] 64
A5(G8) 26 [39] 100 B2(S6) 4 [39] 100
51 [39] 72 65 [39] 83
69 [39] 82 B2(S7) 60 [37] NT
82 [40] 71 B2(S8) 48 [37] 100
A11(G9) 34 [38] 100 50 [37] 66
73 [36] 83
A9(G10) 16 [37] 100
31 [37] 72
33 [37] 66
35 [37] 72
52 [39] 66
58 [38] 67
67 [38] 67
NT means not tested.
a %similarity of whole nucleotide sequences between the first numerical
type and other types from the same group.
b Phylogenetic supergroup (tentative name).
Fig. 1. Blot hybridization analysis of HPVs 16 and 18 sequences. Serially
diluted HPV 16 or HPV 18 cloned DNA was mixed with 5 Ag of placenta
DNA at 0.5, 1, 5, and 10 copies per diploid cell, respectively, and digested
with PstI (P). In addition, 5 Ag of SiHa or HeLa cell DNA and 1 Ag DNA
from CIN or VAIN samples were digested with PstI (P), BanI (B), or MspI
(M). The cleaved products were electrophoresed on a 1% agarose gel and
transferred to a nitrocellulose filter. It was hybridized with HPVs 16 or 18
probes at Tm 20 jC. The size of the PstI-A fragment of both HPVs 16
and 18 is indicated in bp (see Table 2).(CIN) or vaginal intraepithelial neoplasia (VAIN). However,
the signal intensities of cellular sequences were too abundant
to obtain reliable data. To establish a better HPV detection
method, we compared the nucleotide sequences of HPVs in
the databases by CLUSTALW. For the arrangement of data,
we did not totally follow established phylogenetic groupings
as some animal papillomaviruses and HPVs are classified in
the same genital groups, as are HPVs that preferentially
associate with skin warts (de Villiers, 2001). For human
diseases, we classified 88 HPVs into 10 genital groups that
induce cervical or vaginal lesions (Matsukura and Sugase,
2001; Sugase and Matsukura, 1997) and 8 skin groups that
induce distinct skin warts (Ashida et al., 2002; Jablonska et
al., 1997; Orth et al., 2001).
In Table 1, the genital and skin groups are arranged in
descending order of the genome GC content and, for the sake
of simplicity, named G1 to G10 and S1 to S8, respectively.
We show similarities of whole nucleotide sequences between
the first numerical type and other types from the same group.
HPVs of each group share more than 62% similarity (between
HPVs 18 and 54) and exhibit similar GC content. We
considered that a single HPV probe might efficiently detect
Table 2
PstI, BanI, and MspI cleavage patterns of genital human papillomaviruses
HPV 18 39 56 82 16 31 33 35 52 58 67
PstI-A 6337 3317 7409 3892 2818 2832 4605 3403 2765 4544 4921
-B 555 1270 333 3621 1776 1627 2011 1796 2239 1726 2344
-C 457 1049 102 358 1549 1552 1173 1687 928 918 531
-D 441 951 1064 1112 120 546 906 300
BanI-A 2578 3258 4514 4311 3407 6256 5052 4104 3349 4268 3680
-B 2003 755 2241 1349 1936 1139 1497 1125 1667 2166 1822
-C 1438 733 686 904 1619 517 832 947 1065 1390 890
-D 833 677 403 776 430 528 590 916 634
MspI-A 4350 2577 3272 3125 2795 3657 3404 3232 2020 3402 3118
-B 1912 1895 2418 2300 2586 1606 2587 2711 1615 1866 2469
-C 1595 1834 1393 1236 1882 1197 1508 1486 1457 1405 965
-D 1320 697 786 444 1020 387 450 793 653 730
Note: the fragment sizes are indicated in bp.
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with different hybridization conditions to optimize this. Fig. 1
shows representative results with groups G6 and G10. DNA
fragments of HPV 16 or HPV 18 clones were serially diluted
and mixed with 5 Ag of placenta DNA at 0.5, 1, 5, and 10
copies per diploid cell, respectively, and digested with PstI
(P). In addition, 5 AgDNA from either SiHa or HeLa cells and
1 Ag DNA from either CIN or VAIN specimens were digested
with PstI (P), BanI (B), or MspI (M). The cleaved products
were electrophoresed on a 1% agarose gel and transferred to
nitrocellulose. The filter was then hybridized with HPVs 16
and 18 probes at Tm 20 jC. As can be seen, both HPVs 16
and 18 clone DNAwere detected at more than 0.5 copies perFig. 2. Blot hybridization analysis of HPV sequences in SCC. Three microg
electrophoresed on 1% agarose gels. Following transfer to nitrocellulose filters, it w
the lanes represent specimen samples. DNA markers in the outside lanes (M) are f
indicated in bp (Table 2).cell. It was estimated by densitometry that both SiHa and
HeLa cells harbored approximately five copies of both HPVs
16 and 18. In contrast, based on cleavage patterns of their
respective prototypes (Table 2), CIN and VAIN cases har-
bored approximately 500 copies of HPV 16 and 10000 copies
of HPV 18.When HPVs 58 and 45 or HPVs 31 and 59 probes
were hybridized to identical blots at Tm 30 jC, one copy
each of HPVs 16 and 18 DNAwas detected (data not shown).
After similar experiments with all genital and skin
groups, it was predicted that any HPV could be detected
at more than one copy number by blot hybridization at Tm
30 jC using 5 Ag total SCC DNA and different cocktails
of HPV probes including HPVs 61, 71, 43, 6, and 42; HPVs
18, 56, 82, and 34; HPVs 16 and 58; HPVs 57, 41, 78, and
5; and HPVs 1, 65, 60, and 48. We digested total SCC DNA
with PstI, BanI, or MspI, and sequentially hybridized it with
the mixed probe cocktails at first. In addition, we analyzed
SCC samples using single HPVs from each group as a probe
under different stringent conditions (Tm 10 to 40 jC)
and different amounts of total DNA (1–10 Ag). We ulti-
mately decided, however, to identify and characterize HPVs
based on authentic PstI, BanI, and MspI cleavage patterns of
HPV prototypes (Table 1).
HPV types identified by blot hybridization
We examined 294 cases of SCC via our established
detection and identification systems, and representative
results from 50 SCCs are shown in Fig. 2. Each 3-Ag
sample of total DNA was digested with PstI and hybridizedrams of total DNA from 50 SCC samples was digested with PstI and
as hybridized with HPVs 16 and 58 probes at Tm 30 jC. Numbers above
rom an HPV 58-positive SCC digested with PstI, and the fragment sizes are
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the autoradiograph so that a faint positive signal was visible
in samples 5, 20, and 30. It subsequently proved to be
almost possible to identify HPV types entirely by compar-
ison with the distinct PstI patterns of HPV prototypes. From
these comparisons, it was found that HPV 16 was present in
cases 1, 4, 6, 8, 12, 14, 24, 27, 31, 32, 36, 38, 41, 45, and
50; HPV 31 in cases 11, 19, and 25; HPV 52 in cases 5, 10,
29, 33, 37, and 44; and HPV 58 in cases 9, 15, 28, 34, 35,
and 49. However, the HPV type in case 43 could not be
identified. On the other hand, in strict contrast to our
previous analysis of CIN or VAIN, additional off-sized
fragments were frequently recognized as in cases 1, 8, 11,
19, 27, 32, 33, 35, and 41. Furthermore, the amount of viral
DNA was considerably different among the samples that
were tested. For example, it was revealed by densitometry
that sample 14 harbored HPV 16 DNA at a level 2000 times
greater than sample 4, and that sample 29 contained 10000
times more HPV 52 DNA than sample 5.
Overall, 11 genital, but no skin, HPVs were identified by
comparison with authentic cleavage patterns of the respec-
tive prototypes (Table 2). HPVs 18 and 39 (group G6) and
HPV 56 (group G7) were identified without assessing off-
sized fragments (Fig. 3A), whereas HPV 82 (group G8) and
seven HPVs from group G10 were identified either with or
without off-sized fragments (Figs. 3A and 3B). This strong-
ly suggested that a full viral genome was present with no
major deletions in the respective SCCs, although the phys-
ical states were not known. It was estimated that at least five
viral copies were present in each of the SCC samples. We
found, however, that the cleavage patterns in 50 SCCFig. 3. Cleavage patterns of genital HPVs. (A) PstI (P), BanI (B), and MspI (M) cle
probes at Tm 30 jC. The size of the PstI-A fragment of each HPV is indicated i
probes at Tm 30 jC. (C) Patterns of unidentified HPVs detected by an HPV 58 p
The size of the PstI fragment from each specimen is indicated in kb.specimens (termed XB) were different from HPV prototypes
or animal papillomaviruses. Fig. 3C shows representative
results analyzed by an HPV 58 probe at Tm 40 jC. By
probing with different HPVs from different groups, it was
found that the XB cases were closely related to group G10,
strongly suggesting that they might contain HPVs charac-
teristic of group G10 that had some major deletions or
rearrangements. For the identification of the XB group
specimens, it will be necessary to isolate the corresponding
viral clones and sequence them. Finally, in 63 remaining
SCCs analyzed in this study, we did not find any HPV
sequences.
We then compared HPV type-specific distribution in
SCCs. Fig. 4 shows the HPV status of 294 SCC samples
together with those of 386 CIN samples previously pub-
lished by this laboratory (Matsukura and Sugase, 2001).
Each closed square represents one case of SCC and each
single open, double open, and single closed circle represents
one case of CIN I, II, and III, respectively. Groups G1 to G5
and also group G9 were not found in any SCC, whereas
groups G6 to G8 were found in eight (2.7%) SCC cases. In
contrast, group G10 was identified in 173 (59%) SCC cases,
where HPV 16 was predominant, followed by HPVs 58, 52,
and 31. Distinguishable detection frequencies were evident
among different genital groups, strongly indicating a corre-
lation between the nucleotide sequences of the viral
genomes and the potency to induce SCC. In addition,
HPV type-specific distribution was similar between CIN II
or III and SCC, supporting the hypothesis that CIN III is a
true precursor of SCC. The prevalence of different HPV
types was similar among different stage groups and alsoavage patterns of HPVs from groups G6 to G8 detected by HPVs 18 and 82
n bp (see Table 2). (B) Patterns of group G10 detected by HPVs 16 and 58
robe at Tm 40 jC. Numbers above the lanes represent specimen samples.
Fig. 4. Genital HPV types identified in SCC and CIN by blot hybridization. HPV status of 294 SCCs and 386 CINs are shown according to the groups listed in
Table 1. Each single closed square represents one case of SCC, and each single open, double open, and single closed circle represents one case of CIN I, II, and
III, respectively. XB means unidentified HPV.
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rates were not significantly different between the different
HPV profiles (data not shown).
HPV types identified by PCR-direct sequence analysis
Subsequently, we examined 250 of 294 SCCs by PCR.
HPV DNA was amplified with MY11/MY09 primers, and
the amplified products were directly sequenced with GP5+/
GP6+ primers. Because two sequences obtained in individ-
ual samples did not always correspond to the same HPV
type, we compared all 500 sequences obtained in 250 SCCs
to HPV sequences in the database. The results were inter-
preted as indicated in Materials and methods. The cases
analyzed by each sequence primer are indicated in Table 3.
Of 70 SCC samples that were originally positive for HPV
16 by blot hybridization, 53 were positive and 2 were
unidentified (XP) by GP5+/GP6+ primer sequencing.
HPV 16 and XP were identified together in two SCC
specimens by GP5+ and GP6+ primers, respectively. XPand HPV 16 were found in 12 SCCs, and HPV 6 and XP
were identified in one SCC case. Likewise, identification of
HPVs 18, 56, 31, 33, and 35 was confirmed in each of the
corresponding cases. However, HPV 52 and HPV 58 were
not always identified in corresponding cases and different
HPVs, such as HPVs 18, 16, 31, and 33 were found in some
cases. Moreover, HPVs 39, 82, and 67 were also not
identified in all of the corresponding cases. Of 48 SCCs
that were positive for unidentified HPVs (XB) following
blot hybridization, group G10 was identified in 34 cases,
supporting the blot hybridization results, while HPVs 6 and
18 were identified in nine and six cases, respectively. In
addition, multiple HPVs were found in five samples. HPVs
6 and 16 were co-identified in three cases by GP5+ and
GP6+, respectively, whereas HPVs 6 and 18 were found in
one case and HPVs 33 and 16 in an additional case. It was
noteworthy that specimen 158 (Fig. 3C) harbored HPV 18,
259 was negative, 361 contained HPVs 6 and 18, and 462,
564, and 667 contained XP, HPV 16, and both HPV 58 and
XP, respectively. Of 60 SCC s that were negative for HPV
Table 3
HPV types identified in SCCs by PCR-direct sequence analysis
HPV types identified by blot hybridization Total
18 39 56 82 16 31 33 35 52 58 67 Subtotal XB Negative
No. of SCC 2 2 1 3 70 14 3 3 18 25 1 142 48 60 250
G1 HPV 81a [1*] [1*]
G4 HPV 6 [1] [1] [9] [10] [20]
HPV 11 [2] [2]
G6 HPV 18 2 1 3 5 [1*] 15 23 [1*]
HPV 45 [1*] [1*] [3*] [4*]
G7 HPV 56 [1] [1] [1] [2]
HPV 66 [1] [1] [1]
G10 HPV 16 [1*] 53 [2,12*] [2*] 1 [2] 54 [4,15*] 15 [11*] 9 [15*] 78 [4,41*]
HPV 31 10 [4] 1 11 [4] 1 [2] 2 14 [6]
HPV 33 3 2 [1] 5 [1] 3 [1] 8 [2]
HPV 35 1 [2*] 1 [2*] 1 [2*]
HPV 52 2 [1] 2 [1] 2 [1]
HPV 58 5 [12*] 5 [12*] [1*] 5 [13*]
XP [1,1*] [1*] 3 2 [12,3*] [4*] [2] 5 [2,2*] 3 [12,2*] [1] 13 [30,13*] 1 [8,7*] 10 [9,3*] 24 [47,23*]
Negative 4 1 5 3 2 10
XB and XP refer to unidentified HPV sequences.
a No. of cases determined by each sequence primer is indicated, determined by both GP5+ and GP6+ primers [determined only by GP5+ or only by GP6+ is
indicated by an asterisk]. See text for definitions.
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13 cases, HPVs 18, 45, and 56 were found in 19 cases,
HPVs 16 and 31 in 26 cases, and XP was identified in 22
samples. Multiple HPVs were found in 10 cases with HPVs
6 and 16 being identified in three cases by GP5+ and GP6+,
respectively. HPVs 6 and 45 were identified in two cases,
HPVs 11 and 16 in another two cases, and HPVs 56 and 16
in one case.
To determine the primer-specific efficiency for the iden-
tification of HPV, we aligned the primer sequences with the
corresponding regions of the HPV prototypes. As shown in
Table 4, the number of mismatched nucleotides is consid-
erably different between HPV types. HPVs having a rela-Table 4
GP5+ and GP6+ primers
HPV No. of nta mismatches
23 nt/GP5+ 25 nt/GP6+
81 2 2
6 1 2
11 1 2
18 1 1
39 4 3
45 3 0
56 1 3
66 2 4
82 6 4
16 2 0
31 1 3
33 1 2
35 3 0
52 5 2
58 3 2
67 2 2
a Nucleotides.tively high number of primer mismatches, such as HPVs 39,
82, and 52, were not efficiently identified, possibly because
the annealing temperature of cycle sequence is 50 jC. It was
not clear, however, why HPV 6 was identified only by the
GP5+ primer or why HPV 18 was frequently identified by
both primers. For the identification of XP, it will be
necessary to clone the PCR products and sequence them
with vector-sequence primers.
Overall, 240 (96%) of 250 SCC samples were positive
for HPV sequences and 13 genital HPVs were identified.
HPV 16 was found in 123 cases, followed by HPV 18 in 24,
HPV 31 in 20, and HPV 6 also in 20 cases. Multiple HPVs
were identified in 15 SCC cases.
Reexamination of SCCs by blot hybridization
We reexamined the SCC cases in which the HPV status
was not conclusively determined by both PCR and blot
hybridization (Table 3). We digested 10 Ag of total DNA
from each SCC sample with PstI or MspI and hybridized at
Tm 10 jC. In two cases that were originally positive for
HPV 39 by blot hybridization, neither HPV 66 nor HPV 16
probes showed any positive signal in the subsequent hybrid-
izations. Likewise, HPVs 6, 18, and 45 probes showed no
signal in the respective cases that had been shown to be
positive for HPVs 16, 52, and 67 by previous blot hybrid-
ization. On the other hand, HPVs 16, 31, and 33 probes
showed positive signals in some cases that were originally
shown to be positive for HPVs 52 or 58. However, these
signals did not exhibit the authentic cleavage patterns of
HPVs 16, 31, or 33. The results indicate that these SCCs
harbor two different HPV types that cannot be concurrently
detected by either blot hybridization or PCR. In the case of
the SCCs that were originally positive for XB by blot
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signal in the repeat analysis. In SCCs that were negative for
HPV by blot hybridization, HPVs 81, 6, 11, 18, 45, 56, 16,
and 31 probes also showed no signal in the subsequent
analyses. The results strongly indicate that the HPV copy
number detected by PCR was less than 0.05 per cell.
In summary, genital HPV sequences were found in 231
(79%) of 294 SCC specimens by blot hybridization. HPV
16 was found to be predominant, followed by HPV 58 and
HPV 52. By PCR determination, genital HPV sequences
were found in 240 (96%) of 250 SCCs. In these cases, HPV
16 was predominantly found, followed by HPV 18 and HPV
31. HPVs identified by blot hybridization were found at a
level of more than five copies of the whole genome per cell,
whereas those identified purely by PCR were found to be
present at less than 0.05 copies per cell. In addition, multiple
HPVs were found in 29 (12%) of 240 SCCs.Discussion
HPV types identified by blot hybridization
Our present HPV blot hybridization results are in dis-
agreement with other previously published studies using
similar methods as we have found HPVs 16 and 18 in 92
(31%) and 2 (0.7%) of 294 SCC cases, respectively (Fig. 4).
This discrepancy might be explained by differing interpreta-
tions of positive signals that are obtained by this method. We
identified and characterized HPV based on comparisons with
distinct authentic cleavage patterns of HPV prototypes (Figs.
3A and 3B). Upon detection of atypical cleavage patterns, we
concluded that unidentified HPVs (XB) were present, and
that these should be further identified by cloning and se-
quencing analysis (Figs. 1 and 3C). In contrast, positive
signals detected under high stringent conditions have previ-
ously been regarded as a definitive sign of the presence of
targeted-HPV. We postulate, however, that blot hybridization
does not only detect targeted-HPV, as various HPV types
share high sequence similarity and a similar GC content
(Table 1), and the amount of viral DNA is considerably
different between different cases of SCC (Fig. 2).
In published autoradiographs, we find both authentic and
atypical cleavage patterns for HPV 16, but few authentic and
many atypical cleavage patterns for HPV 18 (Boschart et al.,
1984; Corden et al., 1999; Das et al., 1992; Lorincz et al.,
1987; Riou et al., 1990; Shirasawa et al., 1988; Wilczynski et
al., 1988; Yoshikawa et al., 1985). The incidence of HPV 16
and particularly that of HPV 18 in ICC may therefore have
been overestimated. In the only previous published study that
concerns multiple HPV types, 10 of 15 genital HPVs were
identified in 129 (84%) out of 153 ICCs (Lorincz et al., 1992).
HPVs 16 and 18 were found in 72 (43%) and 36 (24%) cases,
respectively, suggesting that HPV 18-associated CIN rapidly
progresses to ICC. It is not possible to examine the validity of
their interpretations without analyzing the autoradiographdata. Because the typing in this previous report was based
on the analysis of PstI patterns only, the results cannot be
compared with our data.
It is noteworthy that authentic and atypical cleavage
patterns of HPV are often interpreted as episomal and
integrated forms of the viral DNA, respectively (Beaude-
non et al., 1986, 1987; Du¨rst et al., 1985). If so, HPVs 18,
39, and 56 were likely to be episomal in the SCC cases in
our study (Fig. 3A). This interpretation, however, is not
necessarily correct because the authentic viral molecules
and the virus-cell junction molecules might be cleaved to
the same size, or the cleaved junction molecules might be
too large, too small, or too little to be detectable under
analytical conditions. Physical states are essentially deter-
mined by analysis with two-dimensional gel electrophore-
sis, although this cannot completely eliminate the
possibility that a very short fragment of the viral genome
is integrated into the cellular DNA. We previously
reported that a complete HPV 16 genome was detectable
as episomal and as integrated forms in 24 and 10 ICC
samples, respectively (Matsukura et al., 1989). It has also
been reported previously that HPV 16 was present in
episomal and integrated forms in 11 and 29 ICC cases
under study, respectively (Cullen et al., 1991). Astonish-
ingly, HPV 18 was found in an integrated form in all 23
ICC cases examined in the same study. Once again, it is
not possible to ascertain the validity of their interpretations
without access to the autoradiograph data.
At present, therefore, little is known about the true
prevalence or the physical states of specific HPV types in
ICC specimens by the use of blot hybridization analysis. It
is generally accepted that HPV DNA is frequently deleted
and integrated in ICC (Einstein and Goldberg, 2002; zur
Hausen, 2002). However, HPV DNA is not frequently
deleted in SCC, as demonstrated in our present study (Figs.
2, 3A, and 3B), together with the fact that none of the six
HPV prototypes cloned from ICCs are deleted (Du¨rst et al.,
1983). Furthermore, HPV is not always integrated in ICC, as
demonstrated in published studies showing unequivocal
identification of HPV (Boschart et al., 1984; Du¨rst et al.,
1985; Matsukura and Sugase, 1990).
HPV types identified by PCR
Our PCR results are likely to be in good concordance
with other published studies, except that HPV 6 was
detected in many of our SCC cases (Table 3, Bosch et al.,
1995; Mun˜oz et al., 2003). This discrepancy may be
explained by the use of different HPV typing methods that
are generally performed by either dot blot or reverse blot
hybridization (Gravitt et al., 1998; Pirog et al., 2000; Qu et
al., 1997; Xi et al., 2003). However, the results do depend
on the number of targeted-HPVs, and there are no stringent
hybridization conditions for unknown amounts of HPV
DNA in the PCR products, as discussed previously in this
report. Thus, we directly sequenced PCR products for the
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amplification of HPV DNA because this method detects
various HPV types, even HPVs of group S4 that induce
unique skin warts or skin cancer (Table 1, Ferrera et al.,
1999; Ishiji et al., 2000). This system worked well in
detecting HPV as 450-bp fragments that were produced in
almost all of the SCC samples (data not shown).
We subsequently used GP5+/GP6+ primers for sequenc-
ing the PCR products, as they are single primers. The GP
primers identified 362/500 sequences, but 118 could not be
identified due to overlapping regions (XP in Table 3). Such
overlapped sequences are regarded as the presence of multi-
ple HPVs in single samples (Huang et al., 1997; Vernon et al.,
2000), but it is necessary, for further identification of HPV
types, to clone PCR products and sequence them with vector-
specific primers. Additionally, because different PCR sys-
tems exhibit different sensitivities and characteristics for the
detection of HPV (Brandsma et al., 1989; Jacobs et al., 2000;
Nindl et al., 1999; Qu et al., 1997), we will need to confirm
our present results using the GP primer system for amplifi-
cation of HPV sequences. Moreover, we need to use a new
system capable of efficiently amplifying specific HPVs other
than the predominant HPVs 16 and 18, as both MY and GP
systems might preferentially and selectively amplify HPVs
16 or 18 when multiple HPVs are present at low copy in a
single SCC. This is because HPVs 16 and 18 have less than
two nucleotide mismatches with two and seven of the eight
MY11 strands, and 8 and 2 of the 16 MY09 strands,
respectively, and also have two mismatches with GP5+ and
one mismatch with the GP6+ strand, respectively (Table 4).
We consider that the presence of partial L1 sequences in
SCCs is not sufficient evidence for causality and it is
necessary to clarify which parts of viral genome persist in
SCC (Corden et al., 1999; Unger et al., 1995).
Is HPV a driver or a passenger in SCC?
By comparative studies using PCR and blot hybridiza-
tion, we found multiple HPVs in 29 of 250 SCC samples
with different pairs of HPVs 6, 11, 16, 18, 31, 33, 39, 45,
52, 56, 58, 66, and 67. The number of HPVs identified in a
single SCC and detection of multiple HPV-associated SCCs
will likely be increased when PCR products are examined
by cloning and sequence analysis. Multiple infections are
not rare in SCC, and given the long period of latency
between the onset of HPV infection and the development
of SCC, and the presence of ubiquitous genital and skin
HPVs in genital regions (Ferrera et al., 1999; Kino et al.,
2000; Peyton et al., 2002), it seems likely that some HPV
types can infect and persist more efficiently in SCC than in
the normal cervical epithelium. Because HPVs 6 and 11
have been exclusively identified in exophytic condyloma
acuminatum but not in CIN by blot hybridization (Matsu-
kura and Sugase, 2001), they may be passengers. There is,
however, no way to conclusively confirm that certain HPV
species are passengers but others are not.Theoretically, we consider that causal HPV must be
present at more than one copy in cancerous cells, and we
question the possible causality of HPV detected by PCR at
less than 0.05 copies per cell (one copy each per 20 cells). Of
course, the HPV copy number cannot be conclusively deter-
mined because the tissue specimens contain a mixture of
normal and neoplastic epithelium and most cancerous cells
are aneuploid. Moreover, the HPV genome is not always a
complete monomer. Within the limitations of the detection,
we did find more than five copies of an entire viral genome in
most SCCs by blot hybridization. It is not known whether
these measurements indicate that there are a few cells with a
large copy number of a viral genome or many cells each with
a small copy number of the viral genomes. Furthermore, HPV
DNA detectable by blot hybridization is not necessarily
present in cancerous cells, as demonstrated in a study of the
HPV 66 prototype (Tawheed et al., 1991). Accordingly, our
results must be confirmed by in situ hybridization for the
determination of causality (Bosch et al., 1995). However,
HPV detectable by blot hybridization may be a valid proof of
the persistence of theHPV genome in SCC for long periods of
time from CIN. On the other hand, the percentage of cancer
versus stromal cells might be low in HPV-negative SCC by
blot hybridization, however, we could find similar histolog-
ical patterns in all SCCs examined. The heterogeneity of
samples may be much more in CIN than in SCC, yet, the lack
of HPV DNA is relatively sizable in SCC (21%), higher than
in CIN III (5%) (Fig. 4). Importantly, all HPV types identified
in SCC by blot hybridization were previously identified in
CIN II or III also by blot hybridization. Although we cannot
systematically ensure an equal probability of representing all
cases of CIN and SCC, our survey studies indicate that HPV
causal for CIN II or III must be a driver of SCC. Because
unscheduled and uncontrolled DNA replication occurs in
SCC, the small 8-kb HPV genome is not likely to be stable in
SCC during the long period of latency. The full viral genome,
however, is able to persist in either episomal or integrated
forms in most cases (Figs. 3A and 3B), yet the quantity of
viral DNA differs significantly between SCC cases (Fig. 2),
in strict contrast to CIN where it is nearly constant (Matsu-
kura and Sugase, 1995). Viral DNA is also rearranged or
deleted in some cases, similar to chromosomal DNA of SCCs
(Fig. 3C), in contrast to CIN where viral DNA remains intact.
Consequently, we speculate that viral DNA, especially in an
episomal form, is lost in some cases, similar to the loss of
constitutional heterozygosity in SCC. Because SCC negative
for HPV by blot hybridization did not cluster at a specific
stage of tumor or at a specific age of the patient, this loss may
occur at any time during or after the establishment of SCC.
The viral driver might not therefore be essential for the
maintenance of SCC.
Unquestionably, a single time-point detection of HPV
DNA does not completely elucidate the causality, and only
longitudinal cohort studies will be able to clarify which
HPV types are drivers and which are only passengers in
SCC. Nevertheless, CIN III must be a valid surrogate end
T. Matsukura, M. Sugase / Virology 324 (2004) 439–449 447point for invasive cancer (Woodman et al., 2003). Thus, we
believe that it will be extremely important to analyze HPV
genomes in CIN III and SCC in survey studies by blot
hybridization.
In conclusion, we cannot obviously specify causal HPV
types in SCC, despite the definitive association, but we
propose three categories of genital HPV genomes in SCC as
follows:
(1) Groups G1 to G5 detectable by PCR but not by blot
hybridization.
(2) Groups G6 to G9 detectable by PCR and rarely by blot
hybridization.
(3) Group G10 detectable by PCR and by blot hybridization.Materials and methods
Clinical specimens and histological examinations
This study was conducted at the Department of Obstetrics
and Gynecology, Nagano Red Cross Hospital in Nagano city,
Japan, from 1986 to 2001. All 294 tissue specimens of SCC
were divided into two parts, of which one was fixed in 10%
buffered formalin for routine histopathology and the other
used for HPV analysis. All of the patients were Japanese
nationals and were immunocompetent. The mean age of the
patients at the time of diagnosis was 58 years (range: 22–90
years). According to the International Federation of Gyne-
cologists and Obstetricians (FIGO), the tumors were classi-
fied as stage Ia in 12 patients, stage Ib in 66 patients, stage II
in 88 patients, stage III in 116 patients, and stage IV in 12
patients.
HPV clones
HPVs 13, 18, 40, 41, 45, 53, and 73, HPV 26, and
HPVs 32, 33, 39, 48, 50, 54, and 66 were kindly provided
by Dr. de Villiers, Dr. Ostrow, and Drs. Favre and Orth,
respectively. Other HPV clones used in the present study
were isolated in our laboratory. Due to a recent decision by
the International Reference Center of Papillomavirus, the
former HPV 62 cloned by us was reclassified as HPV 90
(Matsukura and Sugase, 1995, 2001; Sugase and Matsu-
kura, 1997) and a new HPV 62 was established.
Blot hybridization analysis
We modified the blot hybridization method previously
published (Matsukura and Sugase, 2001) as follows: total
SCC DNAwas digested with an appropriate enzyme in a 20-
Al reaction and the cleaved product was placed into a slot
(0.3  0.3  0.5 cm) on a 1% agarose gel (11  14  0.65
cm with 26 slots). After electrophoresis at 30 V for 13 h 30
min using 40 mM Tris acetate, 2 mM EDTA (pH 8.0) as the
running buffer, the gel was hydrolyzed with 0.2 M HCl.Subsequently, the gel was denatured with 1.5 M NaCl, 0.5
M NaOH, and neutralized with 3.0 M NaCl, 0.5 M Tris–
HCl (pH 7.5). DNA in the gel was transferred to a
nitrocellulose filter (BA 79 or BA 85, Schleicher and
Schuell, Dassel, Germany) under a vacuum using 20
SSC (1 SSC is 0.15 M NaCl, 0.015 M sodium citrate)
as transfer buffer and was cross-linked to the filter by UV
irradiation. The filter was incubated with 10 ml of hybrid-
ization buffer and heat-denatured HPV probes for 12–18
h in a 42 jC bath. The hybridization and washing were done
at various stringent conditions (Tm 10 to 40 jC) using
appropriate buffer conditions for the HPV probes (see GC
content in Table 1). In preparing the probe, DNA fragments
of an entire HPV genome were labeled with [a-32P] dCTP
using random oligonucleotide primers to a spec. act. of 1 
109 cpm/Ag and 1.0  107 cpm probe was used for each
filter. Filters were finally exposed to X-ray film (XAR-5 or
BioMax, Eastman Kodak, Rochester, NY) with intensifying
screens at 80 jC for 3 h to 3 days, and the films were
subsequently developed.
PCR-direct sequence analysis
For PCR analysis, standard methods to both avoid and
monitor for contamination were used throughout the proce-
dure and all samples were tested for DNA integrity by PCR
for the human h-globin gene. To amplify HPV DNA, we
used L1 consensus primers MY11 and MY09 (Manos et al.,
1989). PCR was performed in a final reaction volume of 50
Al, containing approximately 100 ng of sample DNA, 0.5
AM of each MY11 and MY09 primer, 200 AM of each
dNTP, 4.0 mM MgCl2, and 2.6 U of Expand high fidelity
enzyme (Roche Diagnostics GmbH, Mannheim, Germany).
Amplification was carried out on GeneAmp PCR system
9700 (Perkin-Elmer Applied Biosystems, Foster City, CA)
as follows: preheating for 4 min at 95 jC was followed by
40 cycles of 1 min at 95 jC, 1 min at 50 jC, and 2 min at 72
jC, and a final extension of 4 min at 72 jC. Two microliters
of reaction mixture was electrophoresed in a 1.5% agarose
gel and stained with ethidium bromide to confirm the
presence of an approximately 450-bp band. Then, 2 Al of
reaction mixture was treated with Exonuclease I and alka-
line phosphatase (ExoSAP-IT, Amersham Biosciences
Corp., Piscataway, NJ) and used for the cycle sequence
reaction (ABI Prism, Dye Terminator Cycle Sequence kit,
Perkin-Elmer Applied Biosystems) using L1 general pri-
mers GP5+ or GP6+ (de Roda Husman et al., 1995) and
separated on an ABI Prism 3700 DNA Analyzer (Perkin-
Elmer Applied Biosystems).
Finally, we compared two sequences generated in each
sample (approximately 350 and 150 nucleotides by GP5+
and GP6+ primer, respectively) to HPV sequences at the
databases by using the FASTA program. We interpreted the
results as follows: if a sequence of a sample yielded more
than 95% similarity to an HPV prototype, the sample was
considered positive for the HPV. If it yielded 80–94%
T. Matsukura, M. Sugase / Virology 324 (2004) 439–449448similarity to any HPVs, the sample was positive for unde-
termined HPV (termed XP), and if it yielded less than 80%
similarity to any HPVs, the sample was negative for HPV.Acknowledgments
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